Collagenase clostridium histolyticum intralesional injections for the treatment of Peyronie’s disease: a safety profile

Yan, Sylvia; Yap, Tet; Minhas, Suks

doi:10.21037/tau.2016.12.08

Cited by 6 publications

(6 citation statements)

References 10 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Others have commented that the high observed rate of penile fracture needs to be contextualized in a physiologic context differing from non-CCH-related fractures, and may be amenable to conservative management. Doing so may better define practitioners’ and patients’ understanding of the drug’s safety profile ( 39 - 41 ).…”

Section: Non-surgical Managementmentioning

confidence: 99%

Contemporary surgical and non-surgical management of Peyronie’s disease

Wayne

Cordon

2018

Transl. Androl. Urol.

View full text Add to dashboard Cite

Numerous treatments have been proposed for Peyronie’s disease (PD). As the evidence base has expanded, the field of operative and non-operative options for patients has narrowed. Collagenase clostridium hystolyticum (CCH) injection now comprises the medical option, and surgical possibilities entail penile plication, plaque incision/excision and grafting, and prosthesis implantation. Still, questions abound regarding the optimal approach and indication for each of these treatments. We conducted a review of literature exploring the contemporary management of PD with a particular focus on work since the last American Urologic Association’s (AUA) guidelines update for PD. Recent results and discussion indicate trends toward minimal invasiveness, toward a more holistic approach to the PD patient, and away from algorithmic management, galvanized, in part, by data challenging long-held beliefs.

show abstract

Section: Non-surgical Managementmentioning

confidence: 99%

Contemporary surgical and non-surgical management of Peyronie’s disease

Wayne

Cordon

2018

Transl. Androl. Urol.

View full text Add to dashboard Cite

show abstract

“…Molecules such as corticosteroids, verapamil, interferon, and collagenase clostridium histolyticum are commonly used in intralesional therapy 5 . Amongst these, collagenase clostridium histolyticum stands out as the most effective agent, and many studies have proven its effectiveness 1,7‐9 . However, in some countries, this drug is difficult to obtain, and the cost of treatment protocols with this drug can be excessive.…”

Section: Introductionmentioning

confidence: 99%

Intralesional low‐dose methylprednisolone for the treatment of active phase Peyronie’s disease: A single‐centre, preliminary prospective non‐randomised study

Üre

Özen

2020

Int J Clin Pract

View full text Add to dashboard Cite

Aim There are a few types of drugs that can be used in the active phase of Peyronie's disease. Methylprednisolone is a corticosteroid with a strong anti‐inflammatory effect. In this study, we aimed to evaluate the effect of intralesional low‐dose methylprednisolone treatment on patients in the active phase of Peyronie's disease. Patients and Methods Forty‐eight patients suffering from Peyronie's disease active phase symptoms were included in the study. Methylprednisolone was administered intralesionally for 8 weeks, once per week, at a dose of 40 mg. The injection was applied to the plaques, which causes maximum curvature. Patients were evaluated before and after treatment for plaque size, angle of curvature, and erectile dysfunction according to the International Index of Erectile Function‐5 and Peyronie's Disease Questionnaire. Results The mean age of the patients was 61.1 (43‐78) years. The mean duration of the symptoms was 3.4 (0‐9) months. The average plaque size before treatment was 13.6 mm (7.1‐16.8) and after treatment, this value decreased to 10.8 mm (4.3‐14.6) (P: .025). The average scores of Peyronie's Disease Questionnaire elements; symptom severity, penile pain, and bother/discomfort were 12.3, 19.1, and 6.2, respectively, before the treatment. These scores were decreased to 8.9, 9.6, and 4.4, respectively, after treatment. All subgroups of Peyronie's Disease Questionnaire scores were significantly improved after treatment (P: .001, P < .001, P: .045, respectively). No adverse events were observed during or after treatment. Conclusion In order to recover the symptoms and signs, new and easily accessible drugs are required for use in the acute period of Peyronie's disease. In this context, treatment with intralesional low‐dose methylprednisolone in acute phase Peyronie's Disease is a promising and safe treatment option.

show abstract

“…Molecules such as corticosteroids, verapamil, interferon, and collagenase clostridium histolyticum are commonly used in intralesional therapy [5]. Among these, collagenase clostridium histolyticum stands out as the most effective agent, and there are many studies that have proven its effectiveness [1,[7][8][9]. However, in some countries, this drug is difficult to obtain, and the cost of treatment protocols with this drug can be excessive.…”

Section: Introductionmentioning

confidence: 99%

Intralesional Low Dose Methylprednisolone for the Treatment of Active Phase Peyronie’s Disease: A Single Center, Preliminary Prospective Non-Randomised Study

Üre

Özen

2020

Preprint

View full text Add to dashboard Cite

Aim There are few types of drugs that can be used in the active phase of Peyronie's disease. Methylprednisolone is a corticosteroid with a strong anti-inflammatory effect. In this study, we aimed to evaluate the effect of intralesional low dose methylprednisolone treatment on patients in the active phase of Peyronie's disease. Patients and Methods Forty-eight patients suffering from Peyronie's disease active phase symptoms were included in the study. Methylprednisolone was administered intralesionally for 8 weeks, once per week, at a dose of 40 mg. The injection was applied into the plaques, which causes maximum curvature. Patients were evaluated before and after treatment for plaque size, angle of curvature, and erectile dysfunction according to the International Index of Erectile Function-5 and Peyronie's Disease Questionnaire. Results The mean age of the patients was 61.1 (43-78) years. Mean duration of the symptoms was 3.4 (0-9) months. The average plaque size before treatment was 13.6 mm (7.1-16.8) and after treatment, this value decreased to 10.8 mm (4.3-14.6) (p:0.025). The average scores of Peyronie's Disease Questionnaire elements; symptom severity, penile pain and bother/discomfort were 12.3, 19.1 and 6.2, respectively before the treatment. These scores were decreased to 8.9, 9.6 and 4.4, respectively after treatment. All subgroups of Peyronie's Disease Questionnaire scores were significantly improved after treatment (p:0.001, p<0.001, p:0.045, respectively).No adverse events were observed during or after treatment. Conclusion In order to recover the symptoms and signs, new and easily accessible drugs are required for use in the acute period of Peyronie's disease. In this context, treatment with intralesional low dose methylprednisolone in acute phase Peyronie's Disease is a promising and safe treatment option.

show abstract

Collagenase clostridium histolyticum intralesional injections for the treatment of Peyronie’s disease: a safety profile

Cited by 6 publications

References 10 publications

Contemporary surgical and non-surgical management of Peyronie’s disease

Contemporary surgical and non-surgical management of Peyronie’s disease

Intralesional low‐dose methylprednisolone for the treatment of active phase Peyronie’s disease: A single‐centre, preliminary prospective non‐randomised study

Intralesional Low Dose Methylprednisolone for the Treatment of Active Phase Peyronie’s Disease: A Single Center, Preliminary Prospective Non-Randomised Study

Contact Info

Product

Resources

About